|
CMV gB/pp65 eVLPs formulated with GM-CSF as a therapeutic vaccine against CMV-positive tumors. |
| |
|
Employment - VBI Vaccines |
Leadership - VBI Vaccines |
Stock and Other Ownership Interests - VBI Vaccines |
Research Funding - VBI Vaccines |
Patents, Royalties, Other Intellectual Property - VBI Vaccines |
| |
|
Employment - VBI Vaccines |
Stock and Other Ownership Interests - VBI Vaccines |
Research Funding - VBI Vaccines |
| |
|
Employment - VBI Vaccines |
Stock and Other Ownership Interests - VBI Vaccines |
Research Funding - VBI Vaccines |
| |
|
Employment - VBI Vaccines |
Stock and Other Ownership Interests - VBI Vaccines |
Research Funding - VBI Vaccines |
| |
|
Employment - VBI Vaccines |
Stock and Other Ownership Interests - VBI Vaccines |
Research Funding - VBI Vaccines |
| |
|
Employment - VBI Vaccines |
Stock and Other Ownership Interests - VBI Vaccines |
Research Funding - VBI Vaccines |
| |
|
Employment - VBI Vaccines |
Stock and Other Ownership Interests - VBI Vaccines |
Research Funding - VBI Vaccines |
| |
|
No Relationships to Disclose |